A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors

被引：6
|
作者：
Bonomi, M. [1 ]
Bhateja, P. [1 ]
Issa, M. [1 ]
Klamer, B. [2 ]
Pan, X. [2 ]
Blakaj, A. [3 ]
Karivedu, V [1 ]
Mousa, L. [1 ]
Mitchell, D. [5 ]
Gamez, M. [5 ]
Kang, S. [4 ]
Seim, Nolan B. [4 ]
Old, M. [4 ]
Carrau, R. [4 ]
Rocco, J. [4 ]
Blakaj, D. [5 ]
机构：
[1] Ohio State Univ, Div Med Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[3] Yale Univ, Div Radiat Oncol, New Haven, CT USA
[4] Ohio State Univ, Div Otolaryngol, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Radiat Oncol, Columbus, OH 43210 USA
来源：
ORAL ONCOLOGY | 2020年 / 110卷
关键词：
PD-1; inhibitors; Metastatic; Head and neck cancer; Response; Predictors; Immunotherapy; CANCER; IMMUNOTHERAPY; NIVOLUMAB; RECURRENT; INDEX;
D O I：
10.1016/j.oraloncology.2020.104900
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments. Patients and methods: This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Resistance biomarkers in patients with head and neck squamous cell carcinoma treated with cetuximab
    Kamal, Maud
    Leblanc, Olivia
    Vacher, Sophie
    Lecerf, Charlotte
    Jeannot, Emmanuelle
    Klijanienko, Jerzy
    Berger, Frederique
    Hoffmann, Caroline
    Calugaru, Valentin
    Badois, Nathalie
    Chilles, Anne
    Lesnik, Maria
    Krhili, Samar
    Jouffroy, Thomas
    Bieche, Ivan
    Le Tourneau, Christophe
    CANCER RESEARCH, 2018, 78 (13)
  • [42] Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma
    Nghia Nguyen
    Bellile, Emily
    Thomas, Daffyd
    McHugh, Jonathan
    Rozek, Laura
    Virani, Shama
    Peterson, Lisa
    Carey, Thomas E.
    Walline, Heather
    Moyer, Jeffery
    Spector, Matthew
    Perim, Daniel
    Prince, Mark
    McLean, Scott
    Bradford, Carol R.
    Taylor, Jeremy M. G.
    Wolf, Gregory T.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 (07): : 1074 - 1084
  • [43] SEROLOGIC DETERMINANTS OF SURVIVAL IN PATIENTS WITH SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    CLAYMAN, GL
    SAVAGE, HE
    AINSLIE, N
    LIU, FJ
    SCHANTZ, SP
    AMERICAN JOURNAL OF SURGERY, 1990, 160 (04): : 434 - 438
  • [44] Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids
    Hill, Sarah J.
    D'Andrea, Alan D.
    CANCER DISCOVERY, 2019, 9 (07) : 828 - 830
  • [45] Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
    Vellanki, Paz J.
    Marur, Shanthi
    Bandaru, Pradeep
    Mishra-Kalyani, Pallavi Shruti
    By, Kunthel
    Girvin, Andrew
    Chatterjee, Somak
    Singh, Harpreet
    Keegan, Patricia
    Larkins, Erin A.
    Cross, Frank
    Pazdur, Richard
    Theoret, Marc R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Development and validation of a predictive model based on β-Klotho for head and neck squamous cell carcinoma
    Wang, Xiangxiu
    Liu, Hongwei
    Wu, Gang
    Lu, Yan
    Cui, Ying
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [47] EGFR Inhibitors for the Treatment of Squamous Cell Carcinoma of the Head and Neck
    Mehra, Ranee
    Cohen, Roger B.
    Harari, Paul M.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (02) : 176 - 184
  • [48] EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
    Ranee Mehra
    Roger B. Cohen
    Paul M. Harari
    Current Oncology Reports, 2008, 10 : 176 - 184
  • [49] Impact of immune-related adverse events (irAE) onset on disease response and survival in patients (pts) with head-neck cancer treated with immune check point inhibitors (ICI)
    Patel, Reema
    Elghawy, Omar
    Barsouk, Adam
    Kaur, Varinder
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Genomic correlates of response to immune checkpoint inhibitors in advanced head and neck squamous cell carcinoma
    Patel, Nisarg A.
    Vokes, Natalie, I
    Elmarakeby, Haitham
    Hanna, Glenn J.
    Van Allen, Eliezer M.
    CANCER RESEARCH, 2020, 80 (16)
12345